A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer

被引：0
|
作者：
Yasushi Sato
Hiroyuki Ohnuma
Masahiro Hirakawa
Minoru Takahashi
Takahiro Osuga
Yutaka Okagawa
Kazuyuki Murase
Kohichi Takada
Yutaka Kawano
Satoshi Iyama
Tsuyoshi Hayashi
Tsutomu Sato
Koji Miyanishi
Rishu Takimoto
Masayoshi Kobune
Kenji Okita
Toru Mizuguchi
Tomohisa Furuhata
Koichi Hirata
Junji Kato
机构：
[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology
[2] Sapporo Kyoritsu Gorinbashi Hospital,Division of Gastroenterology
[3] Sapporo Medical University School of Medicine,Department of Surgery, Surgical Oncology and Science
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Bevacizumab; Capecitabine; Colorectal cancer; Irinotecan; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：587 / 594
页数：7
相关论文
共 50 条
  • [21] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [22] First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the GONO group
    Burs, S.
    Masi, G.
    Loupakis, F.
    Antonuzzo, A.
    Tognarini, L.
    Sonaglio, C.
    Chiara, S.
    Pfanner, E.
    Brunetti, I
    Petrini, I
    Baldi, G.
    Barletta, M.
    Allegrini, G.
    Ricci, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII27 - VII27
  • [23] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Landre, Thierry
    Maillard, Emilie
    Taleb, Cherifa
    Ghebriou, Djamel
    Des Guetz, Gaetan
    Zelek, Laurent
    Aparicio, Thomas
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (08) : 1125 - 1130
  • [24] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Thierry Landre
    Emilie Maillard
    Chérifa Taleb
    Djamel Ghebriou
    Gaetan Des Guetz
    Laurent Zelek
    Thomas Aparicio
    [J]. International Journal of Colorectal Disease, 2018, 33 : 1125 - 1130
  • [25] Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Boku, Narikazu
    Kato, Ken
    Komatsu, Yoshito
    Yamaguchi, Kensei
    Muro, Kei
    Hamamoto, Yasuo
    Sato, Atsushi
    Koizumi, Wasaburo
    Mizunuma, Nobuyuki
    Takiuchi, Hiroya
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 913 - 920
  • [26] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    [J]. British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [27] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [28] Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study
    Kotani, Daisuke
    Yoshino, Takayuki
    Kotaka, Masahito
    Kawazoe, Akihito
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Yamazaki, Kentaro
    Yamanaka, Takeharu
    Oki, Eiji
    Muro, Kei
    Komatsu, Yoshito
    Bando, Hideaki
    Satake, Hironaga
    Kato, Takeshi
    Tsuji, Akihito
    [J]. INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1649 - 1655
  • [29] A dose-escalation study of docetaxel, oxaliplatin and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
    Sato, Yasushi
    Sagawa, Tamotsu
    Takahashi, Yasuo
    Ohnuma, Hiroyuki
    Hamaguchi, Kyoko
    Hirakawa, Masahiro
    Fujikawa, Koshi
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [30] Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer
    Uchima, Yasutake
    Nishii, Takafumi
    Iseki, Yasuhito
    Ishii, Mariko
    Hiramatsu, Soichiro
    Iwauchi, Takehiko
    Morimoto, Junya
    Kosaka, Kinshi
    Tei, Seika
    Takeuchi, Kazuhiro
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 134 - 138
12345